SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Integrated Cannabis Solutions, Inc. (IGPK) (CIK 0001002771) — Mar 9, 2020

Integrated Cannabis Solutions, Inc. (IGPK) (CIK 0001002771)
Date: March 9, 2020 · CIK: 0001002771 · Accession: 0000000000-20-002119

AI Filing Summary & Sentiment

File numbers found in text: 333-236395

Date
March 9, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Integrated Cannabis Solutions, Inc. (IGPK) (CIK 0001002771)

Letter

March 9, 2020 Matthew Dwyer Chief Executive Officer Integrated Cannabis Solutions, Inc. 6810 North State Road 7 Coconut Creek, FL 33073 Re:Integrated Cannabis Solutions, Inc. Registration Statement on Form S-1 Filed February 12, 2020 File No. 333-236395 Dear Mr. Dwyer: We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form S-1 filed February 12, 2020 Cover Page 1.We note your statement on the cover page that you are a shell company and your disclosure in the Plan of Distribution section that selling security holders "may be deemed to be underwriters...." As Rule 144 is not available for the resale of securities of a shell company, the entire offering is a primary offering and each of the selling security holders is considered an underwriter. See SEC Release 33-8869 (2007). Please revise the registration statement to identify the selling security holders as underwriters. In addition, you must fix the price for the entire duration of the offering because the offering is deemed to be on behalf of the company, and the company is not eligible to use Form S-3 or to conduct an at-the-market offering. Accordingly, please revise your disclosure in the prospectus cover page and prospectus summary, as applicable.

FirstName LastNameMatthew Dwyer Comapany NameIntegrated Cannabis Solutions, Inc. March 9, 2020 Page 2 FirstName LastName Matthew Dwyer Integrated Cannabis Solutions, Inc. March 9, 2020 Page 2 Prospectus Summary Our Future Hemp Processing Business, page 8 2.In your description of future operations, you state that CBD is used for "various therapeutic and healing purposes." Products that are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body are considered drugs under the Federal Food, Drug and Cosmetic Act and subject to FDA approval. Please revise your business section to describe the drug development process, or revise to avoid unsubstantiated therapeutic claims. Risk Factors Because our directors and executive officers are among our largest stockholders, they can exert significant..., page 13 3.Please revise to state that the Chief Executive Officer beneficially owns 97.7% of the outstanding voting stock. Please also revise the cover page accordingly. Rule 144, page 34 4.Please revise to disclose the consequences of your shell company status. In this regard, please disclose the conditions that must be satisfied before restricted and control securities may be resold in reliance on Rule 144. Please also make similar revisions on page 60. Description of Business Business, page 38 5.We refer to your disclosure on page 38 that you plan to "process Hemp or biomass that [you] will acquire or establishing a processing plant in Wisconsin." In addition, we also note information contained on what appears to be your website located at www.igpk.org indicates that you executed a contract to purchase an 200 acre farm and that you are building a state of the art processing plant with enough capacity to handle up to 10 times its 160 acres. Please revise your registration statement to disclose the material terms of your contract to purchase 200 acre farm and file the contract as an exhibit. Additionally, please also clearly disclose the status of your processing plant. Executive Compensation, page 57 6.Please file your employment agreement with your Chief Executive Officer as an exhibit to the registration statement.

FirstName LastNameMatthew Dwyer Comapany NameIntegrated Cannabis Solutions, Inc. March 9, 2020 Page 3 FirstName LastName Matthew Dwyer Integrated Cannabis Solutions, Inc. March 9, 2020 Page 3 General 7.Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. You may contact Julie Sherman at 202-551-3640 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at 202-551-2544 or Celeste Murphy at 202-551-3257 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Frederick M. Lehrer, Esq.

Show Raw Text
March 9, 2020
Matthew Dwyer
Chief Executive Officer
Integrated Cannabis Solutions, Inc.
6810 North State Road 7
Coconut Creek, FL 33073
Re:Integrated Cannabis Solutions, Inc.
Registration Statement on Form S-1
Filed February 12, 2020
File No. 333-236395
Dear Mr. Dwyer:
            We have reviewed your registration statement and have the following comments.  In
some of our comments, we may ask you to provide us with information so we may better
understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1 filed February 12, 2020
Cover Page
1.We note your statement on the cover page that you are a shell company and your
disclosure in the Plan of Distribution section that selling security holders "may be deemed
to be underwriters...."  As Rule 144 is not available for the resale of securities of a shell
company, the entire offering is a primary offering and each of the selling security holders
is considered an underwriter.  See SEC Release 33-8869 (2007).  Please revise the
registration statement to identify the selling security holders as underwriters.  In addition,
you must fix the price for the entire duration of the offering because the offering is
deemed to be on behalf of the company, and the company is not eligible to use Form S-3
or to conduct an at-the-market offering.  Accordingly, please revise your disclosure in the
prospectus cover page and prospectus summary, as applicable.

 FirstName LastNameMatthew Dwyer
 Comapany NameIntegrated Cannabis Solutions, Inc.
 March 9, 2020 Page 2
 FirstName LastName
Matthew Dwyer
Integrated Cannabis Solutions, Inc.
March 9, 2020
Page 2
Prospectus Summary
Our Future Hemp Processing Business, page 8
2.In your description of future operations, you state that CBD is used for "various
therapeutic and healing purposes."  Products that are intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure
or any function of the body are considered drugs under the Federal Food, Drug and
Cosmetic Act and subject to FDA approval.  Please revise your business section to
describe the drug development process, or revise to avoid unsubstantiated therapeutic
claims.
Risk Factors
Because our directors and executive officers are among our largest stockholders, they can exert
significant..., page 13
3.Please revise to state that the Chief Executive Officer beneficially owns 97.7% of the
outstanding voting stock.  Please also revise the cover page accordingly.
Rule 144, page 34
4.Please revise to disclose the consequences of your shell company status.  In this regard,
please disclose the conditions that must be satisfied before restricted and control securities
may be resold in reliance on Rule 144.  Please also make similar revisions on page 60.
Description of Business
Business, page 38
5.We refer to your disclosure on page 38 that you plan to "process Hemp or biomass that
[you] will acquire or establishing a processing plant in Wisconsin."  In addition, we also
note information contained on what appears to be your website located at www.igpk.org
indicates that you executed a contract to purchase an 200 acre farm and that you are
building a state of the art processing plant with enough capacity to handle up to 10 times
its 160 acres.  Please revise your registration statement to disclose the material terms of
your contract to purchase 200 acre farm and file the contract as an exhibit.  Additionally,
please also clearly disclose the status of your processing plant.
Executive Compensation, page 57
6.Please file your employment agreement with your Chief Executive Officer as an exhibit to
the registration statement.

 FirstName LastNameMatthew Dwyer
 Comapany NameIntegrated Cannabis Solutions, Inc.
 March 9, 2020 Page 3
 FirstName LastName
Matthew Dwyer
Integrated Cannabis Solutions, Inc.
March 9, 2020
Page 3
General
7.Please supplementally provide us with copies of all written communications, as defined in
Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf,
present to potential investors in reliance on Section 5(d) of the Securities Act, whether or
not they retain copies of the communications.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
            You may contact Julie Sherman at 202-551-3640 or Lynn Dicker at 202-551-3616 if you
have questions regarding comments on the financial statements and related matters.  Please
contact Jeffrey Gabor at 202-551-2544 or Celeste Murphy at 202-551-3257 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Frederick M. Lehrer, Esq.